Synlogic Inc (SYBX) Expected to Post Earnings of -$0.64 Per Share

Equities research analysts expect Synlogic Inc (NASDAQ:SYBX) to post earnings per share of ($0.64) for the current quarter, according to Zacks. Five analysts have issued estimates for Synlogic’s earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.65). Synlogic posted earnings of ($1.66) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 61.4%. The firm is expected to issue its next quarterly earnings results on Monday, November 12th.

According to Zacks, analysts expect that Synlogic will report full year earnings of ($2.47) per share for the current year, with EPS estimates ranging from ($2.54) to ($2.38). For the next year, analysts expect that the business will post earnings of ($2.84) per share, with EPS estimates ranging from ($3.36) to ($2.41). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Synlogic.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.06). Synlogic had a negative return on equity of 43.51% and a negative net margin of 5,949.04%. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.22 million.

A number of research firms have commented on SYBX. Wedbush restated an “outperform” rating on shares of Synlogic in a research report on Friday, September 7th. HC Wainwright set a $20.00 target price on Synlogic and gave the company a “buy” rating in a research report on Tuesday, October 9th. Citigroup lifted their target price on Synlogic to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 5th. restated a “buy” rating and issued a $18.00 target price on shares of Synlogic in a research report on Tuesday, July 3rd. Finally, Oppenheimer began coverage on Synlogic in a research report on Friday, June 29th. They issued an “outperform” rating and a $18.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $17.93.

NASDAQ:SYBX traded up $0.20 on Friday, reaching $9.46. The company’s stock had a trading volume of 2,262 shares, compared to its average volume of 138,226. Synlogic has a 12-month low of $7.27 and a 12-month high of $17.00. The company has a market capitalization of $251.26 million, a P/E ratio of -1.61 and a beta of 1.71.

In related news, insider Paul Francis Miller sold 3,000 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $12.55, for a total value of $37,650.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 9,000 shares of company stock worth $106,080 in the last quarter. Company insiders own 23.30% of the company’s stock.

Several hedge funds have recently bought and sold shares of SYBX. Northern Trust Corp raised its holdings in shares of Synlogic by 473.8% in the 2nd quarter. Northern Trust Corp now owns 152,491 shares of the biotechnology company’s stock valued at $1,499,000 after buying an additional 125,916 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Synlogic in the 1st quarter valued at $538,000. Element Capital Management LLC purchased a new stake in shares of Synlogic in the 1st quarter valued at $182,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Synlogic in the 1st quarter valued at $120,000. Hedge funds and other institutional investors own 79.39% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: Google Finance

Get a free copy of the Zacks research report on Synlogic (SYBX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with's FREE daily email newsletter.

Leave a Reply